Safety of agents used to prevent mother-to-child transmission of HIV: is there any cause for concern? (Q36753687)

16 August 2017

1 reference

title

Safety of agents used to prevent mother-to-child transmission of HIV: is there any cause for concern? (English)

1 reference

16 August 2017

0 references

1

1 reference

16 August 2017

2

Marie-Louise Newell

0 references

publication date

1 January 2007

1 reference

16 August 2017

1 reference

16 August 2017

30

1 reference

16 August 2017

3

1 reference

16 August 2017

203-213

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-200730030-00004

16 August 2017

0 references

cites work

Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200730030-00004

Safety and efficacy of saquinavir soft-gelatin capsules + zidovudine + optional lamivudine in pregnancy and prevention of vertical HIV transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200730030-00004

After AIDS clinical trial 076: the changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. Women and Infants Tran

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200730030-00004

Zidovudine-associated embryonic toxicity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200730030-00004

Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis

21 January 2018

1 reference

12 December 2020

Safety of antiretroviral prophylaxis of perinatal transmission for HIV-infected pregnant women and their infants

1 reference

12 December 2020

Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.

1 reference

12 December 2020

Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group

1 reference

12 December 2020

Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals

1 reference

12 December 2020

The mother-to-child HIV transmission epidemic in Europe: evolving in the East and established in the West

1 reference

12 December 2020

Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women

1 reference

12 December 2020

Maternal-fetal transfer of saquinavir studied in the ex vivo placental perfusion model

1 reference

12 December 2020

Maternal viral load and vertical transmission of HIV-1: an important factor but not the only one. The European Collaborative Study

1 reference

12 December 2020

Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy

1 reference

12 December 2020

HIV-infected pregnant women and vertical transmission in Europe since 1986. European collaborative study

1 reference

12 December 2020

Management of human immunodeficiency virus infection in pregnancy

1 reference

12 December 2020

Haematological parameters of HIV-1-uninfected infants born to HIV-1-infected mothers

1 reference

12 December 2020

Gender and long-term metabolic toxicities from antiretroviral therapy in HIV-1 infected persons.

1 reference

12 December 2020

Hepatotoxicity associated with nevirapine use.

1 reference

12 December 2020

Antiretroviral therapy-associated modulation of Th1 and Th2 immune responses in HIV-infected pregnant women

1 reference

12 December 2020

Effect of protease inhibitor therapy on glucose intolerance in pregnancy

1 reference

12 December 2020

Antiretroviral therapy during pregnancy and the risk of an adverse outcome

1 reference

12 December 2020

Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe

1 reference

12 December 2020

Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy

1 reference

12 December 2020

Combination antiretroviral therapy and duration of pregnancy

1 reference

12 December 2020

Fetal mitochondrial heart and skeletal muscle damage in Erythrocebus patas monkeys exposed in utero to 3'-azido-3'-deoxythymidine

1 reference

12 December 2020

Serum lactate levels in infants exposed peripartum to antiretroviral agents to prevent mother-to-child transmission of HIV: Agence Nationale de Recherches Sur le SIDA et les Hépatites Virales 1209 study, Abidjan, Ivory Coast

1 reference

12 December 2020

Long-term Outcomes in Infants Born to HIV-Infected Women

1 reference

12 December 2020

Adverse effects of antiretroviral therapy

1 reference

12 December 2020

Placental transfer of ritonavir with zidovudine in the ex vivo placental perfusion model

1 reference

12 December 2020

Antiretroviral Therapy and Congenital Abnormalities in Infants Born to HIV-1-Infected Women in the United Kingdom and Ireland, 1990 to 2003

1 reference

12 December 2020

Zidovudine administration during pregnancy and mitochondrial disease in the offspring.

1 reference

12 December 2020

In utero nucleoside reverse transcriptase inhibitor exposure and cancer in HIV-uninfected children: an update from the pediatric AIDS clinical trials group 219 and 219C cohorts.

1 reference

12 December 2020

Mitochondrial toxicity in hearts of CD-1 mice following perinatal exposure to AZT, 3TC, or AZT/3TC in combination.

1 reference

12 December 2020

Obstetric and newborn outcomes in a cohort of HIV-infected pregnant women: a report of the women and infants transmission study

1 reference

12 December 2020

Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants

1 reference

12 December 2020

Protease inhibitors and decreased birth weight in HIV-infected pregnant women with impaired glucose tolerance.

1 reference

12 December 2020

Drug safety during pregnancy and in infants. Lack of mortality related to mitochondrial dysfunction among perinatally HIV-exposed children in pediatric HIV surveillance.

1 reference

12 December 2020

Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues

1 reference

12 December 2020

Myelomeningocele in a child with intrauterine exposure to efavirenz.

1 reference

12 December 2020

From the Food and Drug Administration

1 reference

12 December 2020

A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients

1 reference

12 December 2020

Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus

1 reference

12 December 2020

Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs

1 reference

12 December 2020

Levels and patterns of neutrophil cell counts over the first 8 years of life in children of HIV-1-infected mothers

1 reference

12 December 2020

Protease inhibitor use during pregnancy: is there an obstetrical risk?

1 reference

12 December 2020

Pre-eclampsia, antiretroviral therapy, and immune reconstitution

1 reference

12 December 2020

Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects

1 reference

12 December 2020

Does Highly Active Antiretroviral Therapy Increase the Risk of Congenital Abnormalities in HIV-Infected Women?

1 reference

12 December 2020

Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission

1 reference

12 December 2020

Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy

1 reference

12 December 2020

Transplacental passage of protease inhibitors at delivery

1 reference

12 December 2020

Transplacentally exposed human and monkey newborn infants show similar evidence of nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity

1 reference

12 December 2020

Mitochondrial damage and DNA depletion in cord blood and umbilical cord from infants exposed in utero to Combivir

1 reference

12 December 2020

Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy

1 reference

12 December 2020

Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022.

1 reference

12 December 2020

Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study

1 reference

12 December 2020

Acceptability and impact of zidovudine for prevention of mother-to-child human immunodeficiency virus-1 transmission in France

1 reference

12 December 2020

Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study

1 reference

12 December 2020

Highly active antiretroviral therapy started during pregnancy or postpartum suppresses HIV-1 RNA, but not DNA, in breast milk

1 reference

12 December 2020

Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth?

1 reference

12 December 2020

Effect of HIV-1 antiretroviral prophylaxis on hepatic and hematological parameters of African infants

1 reference

12 December 2020

A review of studies assessing the costs and consequences of interventions to reduce mother-to-child HIV transmission in sub-Saharan Africa

1 reference

12 December 2020

Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication

1 reference

12 December 2020

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

1 reference

12 December 2020

Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy

1 reference

12 December 2020

Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire

1 reference

12 December 2020

Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: a randomised trial

1 reference

12 December 2020

Genotoxic and functional consequences of transplacental zidovudine exposure in fetal monkey brain mitochondria

1 reference

12 December 2020

Mother-to-child transmission of HIV infection and its prevention

1 reference

12 December 2020

Case report: nucleoside analogue-induced lactic acidosis in the third trimester of pregnancy

1 reference

12 December 2020

Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine

1 reference

12 December 2020

Therapeutic and other interventions to reduce the risk of mother-to-child transmission of HIV-1 in Europe. The European Collaborative Study

1 reference

12 December 2020

Transplacental genotoxicity of combined antiretroviral nucleoside analogue therapy in Erythrocebus patas monkeys

1 reference

12 December 2020

Antiretroviral pharmacology in pregnant women and their newborns.

1 reference

12 December 2020

Effect of antiretroviral agents on carbohydrate metabolism in HIV-1 infected pregnant women

1 reference

12 December 2020

Controversies in the use of nevirapine for prevention of mother-to-child transmission of HIV.

1 reference

12 December 2020

Maternal and infant factors and lymphocyte, CD4 and CD8 cell counts in uninfected children of HIV-1-infected mothers

1 reference

12 December 2020

Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial

1 reference

12 December 2020

Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose nvp prophylaxis: HIVNET 012.

1 reference

12 December 2020

Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group

1 reference

12 December 2020

Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams.

1 reference

12 December 2020

Periconceptional exposure to efavirenz and neural tube defects

1 reference

12 December 2020

Risk of early febrile seizure with perinatal exposure to nucleoside analogues

1 reference

12 December 2020

Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy

1 reference

12 December 2020

10.2165/00002018-200730030-00004

Identifiers

DOI

1 reference

PubMed ID

17343429

Dimensions Publication ID

16 August 2017

0 references

1 reference

PubMed ID

17343429